Although HIF-PHIs can now be used to treat renal anemia, there are potential concerns, which include malignancy and retinopathy due to the activation of the vascular endothelial growth factor (VEGF) and cyst growth in polycystic kidneys. The gene discussed is VEGFA; the disease is polycystic kidney disease.